This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Stopping beta blocker therapy

Authoring team

  • consequences if abrupt withdrawal of a beta blocker
    • worsening angina, myocardial infarction and ventricular dysrhythmias have been observed after abrupt discontinuation of propranolol in patients with coronary artery disease (1)
    • abrupt withdrawal of beta-blocking drugs in patients with hypertension has resulted in transient symptoms, including malaise, headache, sweating, palpitations and increases in blood pressure
    • abrupt withdrawal of beta-blocker perioperatively is associated with increased postoperative mortality (2)
    • if abrupt withdrawal of beta blockers then coronary events have been observed to as late as 3 weeks after abrupt withdrawal of beta blocker therapy (1)

  • gradual withdrawal of beta blocker usage
    • if chronic usage of a beta blocker then beta blocker therapy needs to be gradually withdrawn to minimise the consequences described above
    • the exact definition of how a beta blocker is to be gradually withdrawn is not described in the respective summary of product characteristics
      • however it has been stated (1) that, if chronic beta blocker usage, 14 days of gradual dose reduction before beta blocker withdrawal is necessary to prevent beta-adrenergic supersensitivity (and possibly "rebound" symptoms)
        • if chronic beta blocker usage then the two week period of withdrawal should be considered a minimum - a longer period of withdrawal might be required if a patient is on a high dose beta blocker/has significant co-morbidities such as coronary heart disease
        • if beta blocker therapy is being withdrawn then it seems prudent to regularly monitor pulse and blood pressure of these patients during the withdrawal of beta blocker therapy

Reference:

  1. Nattel S et al. Mechanism of Propranolol Withdrawal Phenomena.Circulation 1979;59:1158-1164
  2. Wallace AW et al. Association of the pattern of use of perioperative beta-blockade and postoperative mortality. Anesthesiology. 2010 Oct;113(4):794-805.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.